Alymsys (bevacizumab-maly) vs HLX04

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline

Alymsys (bevacizumab-maly)

Marketed by Amneal Pharmaceuticals

Approved in Non-Small Cell Lung Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

HLX04 · Hanbeitai

Marketed by Shanghai Henlius Biotech

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03952403 · Phase 3 · status unknown

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

The first listed primary outcome for this study is Part 1 safety and tolerability; the survival figures shown here are the Part 2 primary endpoint (progression-free survival) and the overall-survival secondary endpoint from the final analysis.

Reported efficacy

Part 1 Safety and tolerability of study treatment (baseline to 21 days); Part 2-Progression Free Survival (PFS) as Determined by the IRRC using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (Baseline until disease progression or death, whichever occurs first (up to approximately 24months)): ASTRUM-002 met the primary endpoint of progression-free survival with the combination of serplulimab plus HLX04 (bevacizumab biosimilar) and chemotherapy at interim analysis. A total of 636 patients were randomized 1:1:1 to serplulimab plus HLX04 and chemotherapy (group A), serplulimab plus HLX04 placebo and chemotherapy (group B), or double placebo plus chemotherapy (group C). Serplulimab plus chemotherapy significantly prolonged OS and maintained the PFS benefit compared to chemotherapy; however, the addition of the bevacizumab biosimilar HLX04 did not yield further improvement for first-line treatment of nonsquamous NSCLC. (mixed)

Result source: NCT03952403

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlymsys (bevacizumab-maly)HLX04
PFS, median8.3 vs 8.6vs Avastinwk 52 · n 315NCT03296163—Not reported
OS, median—Not reported—Not reported
ORR40.3% vs 44.6%vs Avastinwk 18 · n 315NCT03296163—Not reported
Duration of response, median—Not reported—Not reported

PFS, median

Alymsys (bevacizumab-maly)
8.3 vs 8.6vs Avastinwk 52 · n 315NCT03296163
HLX04
—Not reported

OS, median

Alymsys (bevacizumab-maly)
—Not reported
HLX04
—Not reported

ORR

Alymsys (bevacizumab-maly)
40.3% vs 44.6%vs Avastinwk 18 · n 315NCT03296163
HLX04
—Not reported

Duration of response, median

Alymsys (bevacizumab-maly)
—Not reported
HLX04
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

HLX04
ASTRUM-002 met the primary endpoint of progression-free survival with the combination of serplulimab plus HLX04 (bevacizumab biosimilar) and chemotherapy at interim analysis. A total of 636 patients were randomized 1:1:1 to serplulimab plus HLX04 and chemotherapy (group A), serplulimab plus HLX04 placebo and chemotherapy (group B), or double placebo plus chemotherapy (group C). Serplulimab plus chemotherapy significantly prolonged OS and maintained the PFS benefit compared to chemotherapy; however, the addition of the bevacizumab biosimilar HLX04 did not yield further improvement for first-line treatment of nonsquamous NSCLC. NCT03952403 · Phase 3 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Alymsys (bevacizumab-maly): 3 of 4 rows · HLX04: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlymsys (bevacizumab-maly)
Dropout rate
34.3%a
NCT03296163 · Phase 3
Discontinued due to AEs
—a
NCT03296163 · Phase 3
Serious AEs
18.6%a
NCT03296163 · Phase 3
Most frequent reported AEs
a
alopecia 49.8%
anemia 32.5%
nausea 15.1%
NCT03296163 · Phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Alymsys (bevacizumab-maly)

ORR 40.3% (n=315) vs 44.6% (n=312) Avastin @ 18wk
responder rate · % of participants
NCT03296163 · Phase 3
PFS 8.31 vs 8.61 Avastin months @ 52wk
time to event · months
NCT03296163 · Phase 3 · converted to months from 36 weeks as posted
Overall Survival NA vs NA Avastin months @ 52wk
time to event · months
NCT03296163 · Phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alymsys (bevacizumab-maly)'s landscape · HLX04's landscape